Randomized controlled trials (RCTs) have evaluated the effects of SGLT2 inhibitors in patients with HF for improving symptoms, mortality, hospitalization, and biomarkers, however results are heterogeneous. The gene discussed is SLC5A2; the disease is hydrops fetalis.